

QLT

[View the current QLT Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/32559-QLT.html) (<http://www.bioportfolio.com/biocorporate/32559-QLT.html>)

Contact Details:

887 Great Northern Way
Vancouver
British Columbia
V5T 4T5
Canada

Tel:
Fax:
Email:

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize two unique technology platforms, photodynamic therapy and Atrigel®, to create products such as Visudyne® and Eligard®. ESTABLISHED Formed in 1981. Became a public company in 1986. FOUNDERS Founded by a group of University of British Columbia professors, including Dr. Julia Levy who served as the Company's President and CEO from 1995 to 2002. EMPLOYEES About 240 professionals located in Vancouver, BC or Fort Collins, CO in the fields of science, research, technology and business.

Recent Publications by QLT:



- [Photodynamic therapy in immune \(non-oncological\) disorders: focus on benzoporphyrin derivatives.](#)
*This review examines the efficacy of photodynamic therapy in the treatment...*24th November, 2007
QLT Inc., Vancouver, British Columbia, Canada.- BioDrugs. 2000 Aug;14(2):127-35.
- [Ultraviolet B light stimulates interleukin-20 expression by human epithelial keratinocytes.](#)
*The proinflammatory cytokine interleukin-20 (IL-20) may exert the majority...*1st June, 2007
Scientific Affairs: Dermatology, QLT, Inc., Vancouver, British Columbia,- Photochem Photobiol. 2006 Sep-Oct;82(5):1292-300. ([DOI Direct Link](#))
- [Lack of effect of sex and disease state on the pharmacokinetics of porfimer sodium.](#)
*BACKGROUND: Porfimer sodium is an agent used for photodynamic therapy...*12th May, 2007
QLT Inc, Vancouver, British Columbia, Canada.- Clin Pharmacokinet. 2006;45(9):923-30.
- [Influence of interleukin-1alpha on androgen receptor expression and cytokine secretion by cultured human dermal papilla cells.](#)
*Dermal papilla cells (DPC) control the growth character of the hair...*12th December, 2006
Scientific Affairs: Dermatology, QLT Inc., 887 Great Northern Way,- Exp Dermatol. 2006

- Oct;15(10):784-93. ([DOI Direct Link](#))
- [Cellular and antitumor activity of a new diethylene glycol benzoporphyrin derivative \(lemuteporfin\).](#)
A newly synthesized diethylene glycol functionalized chlorin-type...14th June, 2006
QLT Inc., 887 Great Northern Way, Vancouver, BC, Canada, V5T 4T5.- Photochem Photobiol. 2006 Jan-Feb;82(1):219-24. ([DOI Direct Link](#))
 - [Rapid induction of apoptosis in human keratinocytes with the photosensitizer QLT0074 via a direct mitochondrial action.](#)
QLT0074 is a newly introduced, porphyrin-derivative for use in...15th April, 2004
Department of Preclinical Pharmacology, QLT Inc., 887 Great Northern Way,- Apoptosis. 2003 Jun;8(3):269-75.
 - [Status of therapies in development for the treatment of age-related macular degeneration.](#)
Age-related macular degeneration (AMD) is among the leading causes of...5th September, 2003
QLT Inc, Preclinical Development, 887 Great Northern Way, Vancouver BC,- IDrugs. 2003 May;6(5):464-9.
 - [Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin.](#)
BACKGROUND: Verteporfin (Visudyne, Novartis AG) is a light-activated drug...4th February, 2003
QLT Inc., 887 Great Northern Way, Vancouver, British Columbia V5T 4T5,- Retina. 2002 Dec;22(6):691-7.
 - [Clinical pharmacokinetics of verteporfin.](#)
Verteporfin, a benzoporphyrin derivative, is the first photo-sensitive...20th December, 2002
QLT Inc., Vancouver, BC, Canada.- J Clin Pharmacol. 2002 May;42(5):547-57.
 - [Selective action of the photosensitizer QLT0074 on activated human T lymphocytes.](#)
A new photosensitizer, presently designated QLT0074, may have the...9th October, 2002
QLT Inc., 887 Great Northern Way, Vancouver, British Columbia, Canada.- Photochem Photobiol. 2002 Aug;76(2):224-31.

BioNews Results for QLT



- [Drug Patent Expirations in October 2008](#)
BioPortfolio: Oct 1 2008 10:27PM Matching: qlt
- [Tekmira Pharmaceuticals Expands Executive Management Team](#)
Nanotechnology News: Sep 30 2008 1:59AM Matching: qlt
- [Tekmira Pharmaceuticals Expands Executive Management Team](#)
TradingMarkets: Sep 29 2008 3:07PM Matching: qlt
- [LifeSciences British Columbia](#)
BioSpace: Sep 27 2008 7:25AM Matching: qlt
- [Michael P. Smith Promoted to CFO at Memory Pha](#)
Citybizlist: Sep 18 2008 6:24PM Matching: qlt
- [Memory Pharmaceuticals Realigns Workforce to Support Development Programs](#)
PR Newswire: Sep 17 2008 11:26PM Matching: qlt
- [QLT Announces Completion of the Redemption of 3% Convertible Senior Notes Due 2023](#)
Pharma Live: Sep 17 2008 5:38AM Matching: qlt
- [Memory Pharmaceuticals Realigns Workforce to Support Development Programs](#)
Montana's News Station: Sep 17 2008 9:55PM Matching: qlt
- [Memory Pharmaceuticals Realigns Workforce to Support Development Programs](#)
KSLA: Sep 17 2008 9:46PM Matching: qlt

- [Memory Pharmaceuticals Realigns Workforce to Support Development Programs](#)
Cincinnati Business Journal: Sep 17 2008 8:36PM Matching: qlt
- [Memory Pharmaceuticals Realigns Workforce to Support Development Programs](#)
Nashville Business Journal: Sep 17 2008 8:36PM Matching: qlt
- [Memory Pharmaceuticals Realigns Workforce to Support Development Programs](#)
Atlanta Business Chronicle: Sep 17 2008 8:30PM Matching: qlt
- [QLT Completes Cdn\\$65.5 million Real Estate Transaction](#)
Pharma Live: Sep 2 2008 1:02PM Matching: qlt
- [QLT completes Cdn\\$65.5 million real estate transaction](#)
Therapeutics Daily: Sep 2 2008 12:26PM Matching: qlt
- [QLT to licence its Atrigel technology to Reckitt Benckiser Pharmaceuticals](#)
Prince George Citizen: Aug 29 2008 4:26PM Matching: qlt

QLT Patents:



- 5707608- [Methods of making liposomes containing hydro-monobenzoporphyrin photosensitizer](#)
- 6100290- [Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases](#)
- 6107325- [Green porphyrins as immunomodulators](#)
- 6117862- [Model and method for angiogenesis inhibition](#)
- 6146409- [Therapeutic methods and devices for irradiating columnar environments](#)
- 6153639- [Ethylene glycol esters as photoactive agents](#)
- 6180402- [Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor](#)
- 6235767- [Methods to treat arterial plaque](#)
- 6248734- [Use of photodynamic therapy for prevention of secondary cataracts](#)
- 6274614- [Methods, compositions and articles for reducing or preventing the effects of inflammation](#)
- 6364907- [Method to prevent xenograft transplant rejection](#)
- 6096776- [Green porphyrins as immunomodulators](#)
- 6086558- [Balloon catheter for photodynamic therapy](#)
- 5756541- [Vision through photodynamic therapy of the eye](#)
- 5834503- [Methods to treat arterial plaque](#)
- 5882328- [Method to prevent transplant rejection](#)
- 5883246- [Synthesis of polypyrrolic macrocycles from meso-substituted tripyrrane compounds](#)
- 5910510- [Vision through photodynamic therapy of the eye](#)
- 5945439- [Method for destroying or inhibiting growth of unwanted cells or tissues](#)
- 6008241- [Green porphyrins as immunomodulators](#)
- 6013053- [Balloon catheter for photodynamic therapy](#)
- 6043237- [Use of photodynamic therapy for prevention of secondary cataracts](#)
- 6074666- [Liposome compositions of porphyrin photosensitizers](#)
- 6548542- [Vision through photodynamic therapy of the eye](#)
- 6599891- [Treatment of macular edema](#)
- 6609014- [Use of PDT to inhibit intimal hyperplasia](#)
- 7090691- [Photodynamic therapy for the treatment of hair loss](#)

- 7105503- [Pyrazole compounds](#)
- 7122568- [Use of low-dose PDT to inhibit restenosis](#)
- 7122569- [Ethylene glycol esters as photoactive agents](#)
- 7128927- [Emulsions for in-situ delivery systems](#)
- 7135193- [Liposome compositions of porphyrin photosensitizers](#)
- 7264629- [Photodynamic therapy for the treatment of hair loss](#)
- 7288556- [Antiproliferative 1,2,3-thiadiazole compounds](#)
- 7347480- [Electromotive sunvisor assembly of a vehicle and the method thereof](#)
- 7393869- [Methods of using thiazolidine derivatives to treat cancer or inflammation](#)
- 7060695- [Method to prevent vision loss](#)
- 7022702- [Antiproliferative 1,2,3-thiadiazole compounds](#)
- 6659107- [Method to prevent xenograft transplant rejection](#)
- 6677366- [Methods, compositions and articles for reducing or preventing the effects of inflammation](#)
- 6756396- [Ethylene glycol esters as photoactive agents](#)
- 6800086- [Reduced fluence rate PDT](#)
- 6830925- [CaMK-X1 and its uses](#)
- 6849058- [Photodynamic therapy in selective cell inactivation in blood and treating immune dysfunction diseases](#)
- 6890555- [Liposome compositions of porphyrin photosensitizers](#)
- 6907679- [Method for lyophilizing an active agent](#)
- 6984395- [Drug delivery system for hydrophobic drugs](#)
- 7015240- [Treatment of macular edema](#)
- 7399462- [Protectant for UV-induced skin damage](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's relate service indepth.

The annual cost is \$495.00 for established organizations and \$295.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

